Canaccord Genuity Maintains a 'Buy' on Hologic (HOLX); Now Largest Pure-Play in Molecular Diagnostics With GPRO Acquisition
Tweet Send to a FriendGet Alerts HOLX Hot Sheet
Price: $21.22 +0.62%
Rating Summary:
16 Buy, 6 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Rating Summary:
16 Buy, 6 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Trade HOLX Now!
Canaccord Genuity maintains a 'Buy' on Hologic (NASDAQ: HOLX) price target of $24.00.
Analyst, Jason R. Mills, said, "We maintain our rating following news that HOLX is acquiring Gen-Probe (Nasdaq: GPRO), which gives HOLX the largest pure play in molecular diagnostics and, most importantly, a highly synergistic, faster-growing women’s’ health asset. We like the acquisition at first blush – namely synergies, and potential for cash flow accretion and growth augmentation. What’s more, we remain bullish about the growth potential of the Breath Health business – namely potential inflection point with 3D Tomo over the next 18-24 months. While this deal is a big bite for HOLX, which understandably raises some concern regarding integration/performance, we believe GPRO is a best-in-class asset that portends obvious synergies that could augment long-term FCF growth."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.12 yesterday, with a 52 week range of $13.90-$23.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason R. Mills, said, "We maintain our rating following news that HOLX is acquiring Gen-Probe (Nasdaq: GPRO), which gives HOLX the largest pure play in molecular diagnostics and, most importantly, a highly synergistic, faster-growing women’s’ health asset. We like the acquisition at first blush – namely synergies, and potential for cash flow accretion and growth augmentation. What’s more, we remain bullish about the growth potential of the Breath Health business – namely potential inflection point with 3D Tomo over the next 18-24 months. While this deal is a big bite for HOLX, which understandably raises some concern regarding integration/performance, we believe GPRO is a best-in-class asset that portends obvious synergies that could augment long-term FCF growth."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.12 yesterday, with a 52 week range of $13.90-$23.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through
- Acquisitions in Focus for Danaher (DHR); Wm. Blair Maintains Outperform
- Wells Fargo Downgrades Ruby Tuesday (RT) to Market Perform
Create E-mail Alert Related Categories
Analyst Comments, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
